This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, G.
Right arrow Articles by Bruckner, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, G.
Right arrow Articles by Bruckner, D. A.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, November 2006, p. 3883-3886, Vol. 44, No. 11
0095-1137/06/$08.00+0     doi:10.1128/JCM.01388-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Increased Vancomycin MICs for Staphylococcus aureus Clinical Isolates from a University Hospital during a 5-Year Period{triangledown}

Guiqing Wang,* Janet F. Hindler, Kevin W. Ward, and David A. Bruckner

Clinical Microbiology Laboratory, Department of Pathology and Laboratory Medicine, UCLA Medical Center, Los Angeles, California 90095-1713

Received 6 July 2006/ Returned for modification 12 July 2006/ Accepted 22 August 2006

Staphylococcus aureus is one of the most commonly isolated organisms in nosocomial infections. While the prevalence of methicillin-resistant S. aureus (MRSA) continues to increase worldwide, there is concern about an increase in vancomycin MICs among S. aureus strains. The prevalence of MRSA and vancomycin MIC trends in S. aureus from patients in a university hospital were analyzed. Clinical Laboratory Standards Institute (CLSI, formerly NCCLS) reference broth microdilution MIC testing was performed on all clinically relevant S. aureus isolates from January 2000 through December 2004. A total of 6,003 S. aureus isolates were analyzed. No vancomycin-resistant S. aureus isolates were detected. One MRSA isolate had a vancomycin MIC of 8 µg/ml and was confirmed as vancomycin-intermediate S. aureus. Among the 6,002 remaining isolates, a shift in vancomycin MICs from ≤0.5 to 1.0 µg/ml was observed during the 5-year period. The percentage of S. aureus isolates with a vancomycin MIC of 1 µg/ml in 2004 was significantly higher than the percentage of isolates in 2000 (70.4% versus 19.9%; P < 0.01). This vancomycin MIC shift was more notable in methicillin-susceptible S. aureus. Our 5 years of routine testing of clinical isolates using the CLSI reference broth microdilution MIC method demonstrated a tendency toward decreasing susceptibility to vancomycin in S. aureus.

* Corresponding author. Mailing address: Clinical Microbiology Laboratory, Medical Center of the University of California at Los Angeles, 10833 LeConte Avenue, Los Angeles, CA 90095-1713. Phone: (310) 794-2766. Fax: (310) 794-2765. E-mail: gw2004{at}gmail.com.

{triangledown} Published ahead of print on 6 September 2006.

Journal of Clinical Microbiology, November 2006, p. 3883-3886, Vol. 44, No. 11
0095-1137/06/$08.00+0     doi:10.1128/JCM.01388-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Musta, A. C., Riederer, K., Shemes, S., Chase, P., Jose, J., Johnson, L. B., Khatib, R. (2009). Vancomycin MIC plus Heteroresistance and Outcome of Methicillin-Resistant Staphylococcus aureus Bacteremia: Trends over 11 Years. J. Clin. Microbiol. 47: 1640-1644 [Abstract] [Full Text]  
  • Mason, E. O., Lamberth, L. B., Hammerman, W. A., Hulten, K. G., Versalovic, J., Kaplan, S. L. (2009). Vancomycin MICs for Staphylococcus aureus Vary by Detection Method and Have Subtly Increased in a Pediatric Population Since 2005. J. Clin. Microbiol. 47: 1628-1630 [Abstract] [Full Text]  
  • Moise, P. A., Smyth, D. S., Robinson, D. A., El-Fawal, N., McCalla, C., Sakoulas, G. (2009). Genotypic and phenotypic relationships among methicillin-resistant Staphylococcus aureus from three multicentre bacteraemia studies. J Antimicrob Chemother 63: 873-876 [Abstract] [Full Text]  
  • Pea, F., Furlanut, M., Negri, C., Pavan, F., Crapis, M., Cristini, F., Viale, P. (2009). Prospectively Validated Dosing Nomograms for Maximizing the Pharmacodynamics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients. Antimicrob. Agents Chemother. 53: 1863-1867 [Abstract] [Full Text]  
  • Forouzesh, A., Moise, P. A., Sakoulas, G. (2009). Vancomycin Ototoxicity: a Reevaluation in an Era of Increasing Doses. Antimicrob. Agents Chemother. 53: 483-486 [Abstract] [Full Text]  
  • Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R. Jr., Craig, W., Billeter, M., Dalovisio, J. R., Levine, D. P. (2009). Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66: 82-98 [Full Text]  
  • Rehm, S. J., Boucher, H., Levine, D., Campion, M., Eisenstein, B. I., Vigliani, G. A., Corey, G.R., Abrutyn, E. (2008). Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 62: 1413-1421 [Abstract] [Full Text]  
  • Pakyz, A. L., MacDougall, C., Oinonen, M., Polk, R. E. (2008). Trends in Antibacterial Use in US Academic Health Centers: 2002 to 2006. Arch Intern Med 168: 2254-2260 [Abstract] [Full Text]  
  • Alos, J.-I., Garcia-Canas, A., Garcia-Hierro, P., Rodriguez-Salvanes, F. (2008). Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J Antimicrob Chemother 62: 773-775 [Abstract] [Full Text]  
  • Wargo, K. A., Eiland, E. H. III, Eiland, L. S. (2008). Management and Treatment Considerations for Infections Caused by Methicillin-Resistant Staphylococcus aureus. Journal of Pharmacy Practice 21: 324-336 [Abstract]  
  • Rybak, M. J., Leonard, S. N., Rossi, K. L., Cheung, C. M., Sadar, H. S., Jones, R. N. (2008). Characterization of Vancomycin-Heteroresistant Staphylococcus aureus from the Metropolitan Area of Detroit, Michigan, over a 22-Year Period (1986 to 2007). J. Clin. Microbiol. 46: 2950-2954 [Abstract] [Full Text]  
  • Chua, T., Moore, C. L., Perri, M. B., Donabedian, S. M., Masch, W., Vager, D., Davis, S. L., Lulek, K., Zimnicki, B., Zervos, M. J. (2008). Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus Bloodstream Isolates in Urban Detroit. J. Clin. Microbiol. 46: 2345-2352 [Abstract] [Full Text]  
  • Burgess, D. S., Rapp, R. P. (2008). Bugs versus drugs: Addressing the pharmacist's challenge. Am J Health Syst Pharm 65: S4-S15 [Abstract] [Full Text]  
  • Olsen, R. J., Burns, K. M., Chen, L., Kreiswirth, B. N., Musser, J. M. (2008). Severe Necrotizing Fasciitis in a Human Immunodeficiency Virus-Positive Patient Caused by Methicillin-Resistant Staphylococcus aureus. J. Clin. Microbiol. 46: 1144-1147 [Abstract] [Full Text]  
  • Holmes, R. L., Jorgensen, J. H. (2008). Inhibitory Activities of 11 Antimicrobial Agents and Bactericidal Activities of Vancomycin and Daptomycin against Invasive Methicillin-Resistant Staphylococcus aureus Isolates Obtained from 1999 through 2006. Antimicrob. Agents Chemother. 52: 757-760 [Abstract] [Full Text]  
  • Sakoulas, G., Rose, W., Rybak, M. J., Pillai, S., Alder, J., Moellering, R. C. Jr., Eliopoulos, G. M. (2008). Evaluation of Endocarditis Caused by Methicillin-Susceptible Staphylococcus aureus Developing Nonsusceptibility to Daptomycin. J. Clin. Microbiol. 46: 220-224 [Abstract] [Full Text]  
  • Sampathkumar, P. (2007). Methicillin-Resistant Staphylococcus aureus: The Latest Health Scare. Mayo Clin Proc. 82: 1463-1467 [Full Text]  
  • Steinkraus, G., White, R., Friedrich, L. (2007). Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001 05. J Antimicrob Chemother 60: 788-794 [Abstract] [Full Text]  
  • Nucifora, G., Badano, L. P., Viale, P., Gianfagna, P., Allocca, G., Montanaro, D., Livi, U., Fioretti, P. M. (2007). Infective endocarditis in chronic haemodialysis patients: an increasing clinical challenge. Eur Heart J 28: 2307-2312 [Abstract] [Full Text]  
  • Daum, R. S. (2007). Skin and Soft-Tissue Infections Caused by Methicillin-Resistant Staphylococcus aureus. NEJM 357: 380-390 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»